NCT06579300 is a Phase 1 clinical trial of ABBV-1088 in Healthy Volunteer, sponsored by AbbVie.

Who is sponsoring NCT06579300?

NCT06579300 is sponsored by AbbVie.

What drugs are being tested in NCT06579300?

Interventions in NCT06579300: ABBV-1088, Placebo for ABBV-1088, Itraconazole (ITZ).

What condition does NCT06579300 study?

NCT06579300 studies Healthy Volunteer.

Is NCT06579300 still recruiting?

NCT06579300 is currently terminated. Last updated 30 October 2025.

Last reviewed 2025-10-30 · How we verify

NCT06579300

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Assess Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pharmacokinetic Study of ABBV-1088

Terminated Phase 1 Last updated 30 October 2025

What this trial tests

Phase 1 trial testing ABBV-1088 in Healthy Volunteer in 72 participants. Terminated before completion.

Timeline

4 September 2024

Primary endpoint
3 September 2025

3 September 2025

Quick facts

Lead sponsor	AbbVie
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	basic science
Enrollment	72
Start date	4 September 2024
Primary completion	3 September 2025
Estimated completion	3 September 2025
Sites	2 locations across United States

Drugs / interventions tested

ABBV-1088 — full drug profile →
Placebo for ABBV-1088 — full drug profile →
Itraconazole (ITZ) — full drug profile →

Conditions studied

Healthy Volunteer — all drugs for Healthy Volunteer →

Sponsor

AbbVie — full company profile →

Who can join

18 and older, any sex, with Healthy Volunteer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will assess the safety, tolerability, and pharmacokinetics of ABBV-1088 in healthy adult Western, Han-Chinese and Japanese participants. This study will also assess drug-drug interaction between itraconazole and ABBV-1088 in healthy adult Western participants.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Mitophagy's impacts on cancer and neurodegenerative diseases: implications for future therapies.
Huang J, Pham VT, Fu S, Huang G, et al · · 2025 · cited 5× · PMID 40750884 · DOI 10.1186/s13045-025-01727-w
Mitophagy-NLRP3 Inflammasome Crosstalk in Parkinson's Disease: Pathogenic Mechanisms and Emerging Therapeutic Strategies.
Ahmed S, Pasam T, Afreen F. · · 2026 · cited 2× · PMID 41516359 · DOI 10.3390/ijms27010486
Targeting of kinases to treat neurodegenerative diseases.
Shomali T, Trempe JF. · · 2026 · cited 1× · PMID 41880688 · DOI 10.1016/j.pharmr.2026.100128
Mitophagy in the pathogenesis and management of disease.
Wang Q, Sun Y, Li TY, Auwerx J. · · 2026 · cited 1× · PMID 41486294 · DOI 10.1038/s41422-025-01203-7
Sources of Oxidative Stress in Parkinson's Disease: Pathways and Therapeutic Implications.
Yordanov Y, Stefanova D, Kondeva-Burdina M, Tzankova V. · · 2026 · PMID 41750568 · DOI 10.3390/antiox15020187

Verify or expand the search:

Other recruiting trials for Healthy Volunteer

Currently open trials in the same condition.

NCT06274749 — Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Mask · NA · recruiting
NCT05652478 — Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized Study · Phase 2 · recruiting
NCT06845176 — Combining Motor Imagery and Tendon Vibration on the Effectiveness of Motor Imagery · NA · recruiting
NCT07439263 — Single Ascending Dose Study of HB2198 in Healthy Participants · Phase 1 · recruiting
NCT07220122 — Impact of Exogenous Ketones on Breathing in Healthy Volunteers · EARLY_PHASE1 · recruiting

Other AbbVie trials

Trials by the same sponsor.

NCT07219017 — A Study to Assess the Mass Balance of Oral ABBV-1354 in Healthy Adult Male Participants · Phase 1 · completed
NCT05316220 — A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years W · Phase 3 · withdrawn
NCT07024797 — Study to Assess the Adverse Events, Tolerability, and How Oral Doses of ABBV-932 Moves Through the Body in Healthy Adult · Phase 1 · completed
NCT07058051 — Cross-sectional Study to Characterize Real World Burden of Disease in Patients With Vitiligo in China · completed
NCT07007091 — A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administrations With a Pre-Filled · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06579300 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AbbVie
Last refreshed: 30 October 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06579300.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing